pacira-bioscience-logO.png
Pacira BioSciences to Present at Two Healthcare Conferences in November
November 08, 2022 08:00 ET | Pacira BioSciences
TAMPA, Fla., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare...
pacira-bioscience-logO.png
Pacira BioSciences Reports Third Quarter 2022 Financial Results
November 03, 2022 08:00 ET | Pacira BioSciences
-- Third quarter revenue of $167 million, increased 31% over prior year ---- Conference call today at 8:30 a.m. ET -- TAMPA, Fla., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc....
pacira-bioscience-logO.png
Pacira to Report Third Quarter 2022 Financial Results on Thursday November 3, 2022
October 20, 2022 08:00 ET | Pacira BioSciences
TAMPA, Fla., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on...
pacira-bioscience-logO.png
Pacira BioSciences Reports Preliminary Third Quarter 2022 Revenue of $167.5 Million
October 13, 2022 08:00 ET | Pacira BioSciences
TAMPA, Fla., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today...
pacira-bioscience-logO.png
Sevāredent Sourcing Solutions and Pacira BioSciences Collaborate to Provide Expanded Access to EXPAREL for Patients Undergoing Oral and Maxillofacial Procedures
September 27, 2022 08:00 ET | Pacira BioSciences
TAMPA, Fla., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Sevāredent Sourcing Solutions, a Group Purchasing Organization (GPO) that creates a competitive advantage for like-minded dental organizations through...
pacira-bioscience-logO.png
Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy
September 21, 2022 08:00 ET | Pacira BioSciences
-- Second Phase 3 study achieves primary and key secondary endpoints; safely demonstrating statistically significant reductions in postsurgical pain and opioid consumption through 96 hours -- --...
pacira-bioscience-logO.png
Pacira Receives Positive CHMP Opinion for EXPAREL® for the Treatment of Postsurgical Pain in Children Aged 6 or Older
September 20, 2022 08:00 ET | Pacira BioSciences
TAMPA, Fla., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the leading global provider of non-opioid pain management options, announced that the European Medicines...
pacira-bioscience-logO.png
Pacira BioSciences Reports Preliminary Net Product Sales of $59.1 Million for August 2022
September 13, 2022 08:00 ET | Pacira BioSciences
-- EXPAREL average daily sales for August 2022 were 108 percent of August 2021 – -- More than 11 million patients have received EXPAREL since launch -- TAMPA, Fla., Sept. 13, 2022 (GLOBE NEWSWIRE)...
pacira-bioscience-logO.png
Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Femoral Nerve Block in the Adductor Canal for Total Knee Arthroplasty
September 07, 2022 07:00 ET | Pacira BioSciences
TAMPA, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today...
pacira-bioscience-logO.png
Pacira BioSciences Reports Preliminary Net Product Sales of $50.2 Million for July 2022
August 10, 2022 08:00 ET | Pacira BioSciences
-- EXPAREL average daily sales for July 2022 were 105 percent of July 2021 -- TAMPA, Fla., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its...